GeneDx Holdings (WGS) Change in Accured Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Change in Accured Expenses for 7 consecutive years, with -$13.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 221.66% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 139.42% YoY), while the FY2025 annual figure was $12.1 million, up 158.96% from the prior year.
• Change in Accured Expenses eased to -$13.2 million in Q1 2026 per WGS's latest filing, from $6.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $31.8 million in Q2 2022 and bottomed at -$14.5 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged -$2.1 million across 5 years, with a median of -$4.7 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 369.89% — and 2023, when it plunged 440.79%.
• GeneDx Holdings' Change in Accured Expenses stood at $5.9 million in 2022, then tumbled by 256.79% to -$9.3 million in 2023, then tumbled by 37.42% to -$12.7 million in 2024, then surged by 154.38% to $6.9 million in 2025, then tumbled by 290.43% to -$13.2 million in 2026.
• Business Quant data shows WGS's Change in Accured Expenses at -$13.2 million in Q1 2026, $6.9 million in Q4 2025, and -$2.0 million in Q3 2025.